Gilead Sciences, Inc.
Gilead Sciences, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Foster City, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $29 billion and a profit of $8.5 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2836, Biological Products, (No Diagnostic Substances)); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.7 out of ten, 9 of 9 metrics filed: past 7.1 out of ten, present 7.5 out of ten, future 5.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2017. 80th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 6.2 out of ten. -0.4% a year over 10 filed years; profitable in 10 of 10. 62nd percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.6 out of ten. Share count shrank 0.2% a year. 55% of cash flow returned. Insiders: 79 sales, 0 purchases. 76th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.5 out of ten. ROE 38%: 38¢ of profit per shareholder dollar. Leverage 62%: owes 62¢ per asset dollar. 75th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.9 out of ten. top 21% of 102 in its family; net margin 28.9%. 79th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 7.0 out of ten. top 30% of 108 in its family for leadership; chief executive since 2019. 70th percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.4 out of ten. bottom 44% of 92 in its family for room to expand. 44th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 6.0 out of ten. top 40% of 100 in its family for growth drivers. 60th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 6.1 out of ten. top 39% of 72 in its family for expectations against reality. 61st percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form 4, 2026-10-02. Filings on record since 1994. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: HIV Products Biktarvy 49%, Oncology Product 11%, Cell Therapy Products Total Cell Therapy Product Sales 6%, HIV Products Genvoya 5%, Trodelvy 5%, Liver Disease Products Sofosbuvir Velpatasvir 4%. By geography: United States 71%, Europe 17%, Rest of World 12%. As tagged in its annual report (Form 10-K, filed 2026-02-24).
Who runs it
O'Day, Daniel Patrick (Chairman & CEO); Dickinson, Andrew D (Chief Financial Officer); Mercier, Johanna (Chief Comm & Corp Aff Officer); Berger, Dietmar (Chief Medical Officer); Burkhart, Erin (SVP, Controllership); Cain, Wettan Keeley M (EVP Gen Counsel, Legal & Comp); Telman, Deborah H (EVP, Corporate Affairs & GC); Wilfong, Diane E. (Interim Corp Controller & CAO); Welters, Anthony (director); Bluestone, Jeffrey (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-02.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.